艾滋病与临床研究杂志

Evaluation of an LSDV-Vectored Vaccine for Heterologous Prime-Boost HIV Immunisations

Abstract

Mertr Toerder

The quest for an effective HIV vaccine has been ongoing for decades, and despite significant progress in understanding the virus and developing prevention and treatment strategies, a prophylactic vaccine remains elusive. Heterologous prime-boost vaccination strategies, involving the use of different vaccine vectors for initial priming and subsequent boosting, have shown promise in inducing robust and durable immune responses. This article explores the evaluation of a novel approach: using Lumpy Skin Disease Virus (LSDV) as a vector for heterologous prime-boost HIV immunizations. HIV (Human Immunodeficiency Virus) is a complex and highly mutable virus that has defied conventional vaccine development strategies.